![](https://news.europawire.eu/wp-content/uploads/2020/05/Rare-disease-Enhertu-of-AstraZeneca-and-Daiichi-Sankyo-now-with-Orphan-Drug-Designation-in-the-US-for-treatment-of-gastric-cancer-144x144.jpg)
(PRESS RELEASE) CAMBRIDGE, 22-May-2020 — /EuropaWire/ — Enhertu, jointly developed by British-Swedish multinational pharmaceutical and biopharmaceutical company AstraZeneca and the second-largest pharmaceutical company in Japan Daiichi Sankyo (Daiichi Sankyo Company, Limited), has just been granted Orphan Drug Designation (ODD) in … Read the full press release